Finance

Beta
Lists
MPLT:NASDAQ
MapLight Therapeutics Inc
$31.96
+4.27%
(+1.31) 1D
$31.96
0.00% (0.00)
After hours
Closed: Jun 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MPLT...
Open
$30.88
High
$32.47
Low
$30.86
Mkt. cap
1.45B
Avg. vol.
340.42K
Volume
463.26K
52-wk high
$33.28
52-wk low
$12.25
Shares outstanding
42.62M
No. of employees
133
Open
$30.88
High
$32.47
Low
$30.86
Mkt. cap
1.45B
Avg. vol.
340.42K
Volume
463.26K
52-wk high
$33.28
52-wk low
$12.25
Shares outstanding
42.62M
No. of employees
133
News stories
From sources across the web
About MapLight Therapeutics Inc
CEO-
Employees133
Founded2018
HeadquartersRedwood City, California, United States
SectorBiotechnology
Websitemaplightrx.com
Analyst ratings
Based on 10 analysts giving stock ratings to MPLT in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for MPLT in the last 3 months.
Highest
Current $31.96
$48.00 (+50.19%)
Average
$41.22 (+28.97%)
Lowest
$34.00 (+6.38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tiago Fauth
Raymond James
Buy
Initiated
$46.00
+43.9%
06/25/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
$40.00
+25.2%
06/23/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$34.00
+6.4%
06/22/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$45.00
+40.8%
06/23/2026
Ami Fadia
Needham
Buy
Reiterated
$42.00
+31.4%
06/22/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$45.00
+40.8%
06/23/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$36.00
+12.6%
06/02/2026
Ashwani Verma
UBS
Buy
Initiated
$48.00
+50.2%
05/27/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$35.00
+9.5%
05/15/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/14/2026
Last report
May 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.34 / -$1.12
-19.91%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
26.85M
27.09M
64.62M
53.68M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.82M
4.40M
18.75M
10.82M
Operating expense
30.66M
31.50M
83.38M
64.50M
Total operating expenses
30.66M
31.50M
83.38M
64.50M
Operating income
-30.66M
-31.50M
-83.38M
-64.50M
Other non operating income
-66.00K
531.00K
-83.00K
549.00K
EBT including unusual items
-29.85M
-29.42M
-79.55M
-60.67M
EBT excluding unusual items
-30.04M
-29.42M
-80.99M
-61.48M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29.85M
-29.42M
-79.55M
-60.67M
Net profit margin
-
-
-
-
Earnings per share
-
-
-2.47
-1.34
Interest and investment income
688.00K
1.55M
2.47M
2.47M
Interest expense
-
-
-
-
Net interest expenses
688.00K
1.55M
2.47M
2.47M
Depreciation and amortization charges
-
-
-
-
EBITDA
-30.53M
-31.36M
-83.24M
-64.34M
Gain or loss from assets sale
-
7.00K
-
4.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of MPLT
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer